Dr. Andrew Allen is Peptone’s Executive Chairman and a member of its board. He co-founded and led Gritstone bio and Clovis Oncology, where he oversaw development of rucaparib, and previously held clinical development roles at Pharmion, Chiron, Abbott, and McKinsey; he studied medicine at Oxford and earned a PhD in immunology from Imperial College London.
Executive Chairman